RespireRx Pharmaceuticals Inc (RSPI)

[senderos]

RespireRx Pharmaceuticals Inc. Announces that Sleep Review has Discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition

Glen Rock, N.J., August 8, 2022 / Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Sleep Review Magazine has published, in its June 13, 2022 edition, a free e-book entitled “How Close Are We to Drug Therapy for Obstructive Sleep Apnea?”, in which it discusses the RespireRx dronabinol OSA program as one of four emerging drug treatments for the treatment of OSA. (https://sleepreviewmag.com/sleep-disorders/breathing-disorders/obstructive-sleep-apnea/how-close-drug-therapy-obstructive-sleep-apnea/).

Editor Sree Roy stated, “For decades, scientists have been searching for a drug therapy for obstructive sleep apnea (OSA)… An oral pharmacologic treatment that keeps airways open during sleep would be a game-changer… An oral pharmacologic treatment would represent a shift in the perception of sleep apnea therapy, likely resolving adherence obstacles associated with medical device-based treatments for many patients. It could also lead to increased willingness among people with OSA symptoms to undergo sleep testing. I wonder how many people who experience excessive daytime sleepiness refuse diagnosis because they are intimidated by currently available sleep apnea treatment options (or at least by their limited knowledge of available treatments)? Sleep specialists too would also welcome another treatment option—more thera¬pies mean more opportunities to find a therapy most compat¬ible to every patient.”

Two Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to significantly reduce the symptoms of OSA and, subject to raising sufficient financing (of which no assurance can be provided) and pending the outcome of an intended meeting with the FDA, RespireRx believes that it will be able to commence a pharmacokinetic study for a recently discovered and to-be-developed formulation followed by a Phase 3 clinical study for the treatment of OSA with the new formulation.

“Dronabinol is being developed by ResolutionRx, a business unit of the RespireRx. It will be my pleasure to discuss with colleagues the latest developments in pharmaceutical cannabinoids and meet with potential business partners,” said Dr. Lippa